Enspryng
What Enspryng is used for
Satralizumab (Enspryng) is indicated as a monotherapy or in combination with immunosuppressive therapy (IST) for the treatment of neuromyelitis optica spectrum disorders (NMOSD) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 IgG (AQP4-IgG) seropositive.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Enspryng
- Active substance
- satralizumab
- Disease area
- Neuromyelitis Optica
- Medicine group
- Immunosuppressants
- ATC code
- L04AC
- Marketing authorisation holder
- Roche Registration GmbH
- Authorised in the EU since
- 2021
Official information
In the USA
Same active substance: Enspryng
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Enspryng used for?
Satralizumab (Enspryng) is indicated as a monotherapy or in combination with immunosuppressive therapy (IST) for the treatment of neuromyelitis optica spectrum disorders (NMOSD) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 IgG (AQP4-IgG) seropositive.
What is the active substance in Enspryng?
Enspryng contains satralizumab.
Who makes Enspryng?
The EU marketing authorisation holder is Roche Registration GmbH.
Is Enspryng an orphan medicine?
Yes. Enspryng is designated an orphan medicine in the EU, for a rare disease (Neuromyelitis Optica).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU